The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2025 | Mosun-Len in patients with R/R follicular lymphoma: US extension cohort from the CELESTIMO study
Dahlia Sano, MBBCH, University of Michigan Rogel Cancer Center, Ann Arbor, MI, discusses the promising results of the US extension cohort from the Phase III CELESTIMO study (NCT04712097), which evaluated the combination of mosunetuzumab and lenalidomide (Mosun-Len) in patients with relapsed/refractory (R/R) follicular lymphoma (FL). The combination demonstrated a tolerable toxicity profile and significant response rates. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Our abstract 800 represents the Arm C, which is the U.S. Extension Arm. The CELESTIMO study is not mentioned, however, the study mentioned is a randomized phase three trial comparing Mosun with Len versus Rituximab and Len. The Extension Arm C is basically looking for improving the U.S. footprint of the study and improving enrollment in the United States. The Extension Arm C includes 54 patients in the U...
Our abstract 800 represents the Arm C, which is the U.S. Extension Arm. The CELESTIMO study is not mentioned, however, the study mentioned is a randomized phase three trial comparing Mosun with Len versus Rituximab and Len. The Extension Arm C is basically looking for improving the U.S. footprint of the study and improving enrollment in the United States. The Extension Arm C includes 54 patients in the U.S. across 15 sites across the U.S. The data is very promising, which showed a very tolerable toxicity profile. The CRS was mostly grade one and the infection risk was mostly grade two at 57%. Responses were very significant, response at 97% and CR at 87%. So of course we wait for the full publication of the randomized portion of the trial. I think this is a very promising combination, very effective and very safe combination as well, and we’re looking forward to using that in the clinic.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
